RxDoctor Payments Data

Martin Bell, MD

Radiation Oncology · Manhattan, KSNPI 1447316047

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 26.8% of the total. Reporting peaked in 2020 at $42 and has fallen 68.9% since, to $13 in 2022. That places this record below the midpoint for radiation oncology clinicians in KS, where the typical reported total is $776.

$82in general payments, 2019–2025

Across 5 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$22
  • Varian Medical Systems, Inc.$20
  • Sanofi$16
  • Siemens Medical Solutions USA, Inc.$13
  • AstraZeneca$11

What the payments were for

  • Food & beverage$82100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$82 in reported general payments places this provider in the 10th percentile of 54 radiation oncology providers in Kansas.

See all radiation oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$1,226,635
Medicare patients
454
Services billed
7,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lidocaine Hcl ViscousLidocaine Hcl12$76

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Manhattan

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →